Effect of spironolactone on left ventricular function and serum chemerin in patients with chronic heart failure
WANG Ya-ling, ZHANG Yang, LIU Tao, GUO An-jun, WANG Mei
2020, 41(7):
749-753.
doi:10.3969/j.issn.1007-3205.2020.07.002
Asbtract
(
681 )
PDF (406KB)
(
118
)
Related Articles |
Metrics
Objective〖HTSS〗To investigate the effect of spironolactone on left ventricular function and serum chemoin in patients with chronic heart failure.
〖WTHZ〗Methods〖HTSS〗Eighty patients with chronic heart failure were randomly divided into a control group and a research group. The control group received conventional treatment, and the research group received spironolactone treatment based on the control group. Compare the levels of inflammatory factors before and after treatment in the two groups [hypersensitive C-reactive protein(hs-CRP), interleukin 6(Interleukin-6, IL-6), tumor necrosis factor-α(tumor necrosis factor-α, TNF-α)], blood lipid levels [low density lipoprotein cholesterol(LDL-C), total cholesterol(TC), triglyceride(TG)], cardiac function [left ventricular end systole Left ventricular end systolic volume(LVESV), left ventricular ejection fraction(LVEF), left ventricular end diastolic volume(LVEDV)], 6 min walking distance, serum vascular endothelial growth factor(VEGF), chemerin, Brain natriuretic peptide(BNP) level and stress response.
〖WTHZ〗Results〖HTSS〗After treatment, the levels of hs-CRP, IL-6, TNF-α, LDL-C, TC, TG, LVESV, LVEDV, VEGF, chemerin, BNP, and MDA were significantly lower than before treatment, and LVEF, AOA, GPx were high Before treatment, the 6-minute walking distance was longer than before treatment. The levels of hs-CRP, IL-6, TNF-α, LDL-C, TC, TG, LVESV, LVEDV, VEGF, chemerin, BNP, and MDA were lower in the study group than in the control group. , LVESV, LVEF, LVEDV, AOA, and GPx were higher than the control group, and the control group with a 6-minute walking distance was significantly different (P<0.05 or P<0.01).
〖WTHZ〗Conclusion〖HTSS〗Spironolactone is effective in the treatment of patients with chronic heart failure. It can reduce inflammatory factors, blood lipid levels and stress responses, improve patients cardiac function, increase 6-minute walking distance, and improve serum VEGF, Chemerin, and BNP levels. It is worthy of clinical promotion.